Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitor evaluation in intracranial atherosclerotic stenosis using MR-VPD
ChiCTR2200062305Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jul 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of atorvastatin and rosuvastatin in Cerebral atherosclerotic stenosis (ICAD) and cerebrovascular disease (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: LDL-C value, Degree of vascular stenosis and 3 more. Started Jul 2022; status: recruiting.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
Cerebral atherosclerotic stenosis (ICAD)cerebrovascular disease
Beyond the preview
Go deeper on ChiCTR2200062305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062305.